Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor
- 13 June 2011
- journal article
- case report
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 53 (1) , 70-72
Abstract
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP‐IV) dysregulation is present in DM and psoriasis, DPP‐IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP‐IV inhibitor. The role of DPP‐IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP‐IV inhibitors and their relationship with DM and psoriasis.Keywords
This publication has 13 references indexed in Scilit:
- Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the EnzymeCurrent Medicinal Chemistry, 2009
- Pattern Analysis of Drug-Induced Skin DiseasesThe American Journal of Dermatopathology, 2008
- CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changesBritish Journal of Dermatology, 2008
- Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markersArchives of Dermatological Research, 2008
- SitagliptinCardiology in Review, 2007
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control studyBritish Journal of Dermatology, 2007
- Inhibitors of Dipeptidyl Peptidase IV and Aminopeptidase N Target Major Pathogenetic Steps in Acne InitiationJournal of Investigative Dermatology, 2007
- Risk of Myocardial Infarction in Patients With PsoriasisJAMA, 2006
- Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6)International Journal of Dermatology, 2005